Skip to main content
Caplight Logo









Oncovita

Oncovita

Private
ParisHealthcare & Life Scienceshttps://oncovita.fr

Last Round

VC Round

Jun 25, 2026

Total Funding Raised

$8.78M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Oncovita operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was an Angel round in November 2023.

Oncovita is a biotechnology company that develops virus-derived vaccine technology to treat various types of cancers and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Oncovita Comparables

Compare Oncovita with similar companies based on industry and business-model similarity.

Oncovita comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CanVirex AG
85%
Vyriad
83%
Imugene Ltd
78%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Oncovita Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 25, 2026
AngelNov 29, 2023
GrantNov 29, 2023
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Stephane Altaba

CEO

Executive Team

For institutional investors. Book with your work email.

Oncovita Investors

Notable investors and investment history

Oncovita investors
InvestorRounds
BpifranceGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    $23M raised in a VC Round.

  • May 14, 2026

    Monthly visitors increased 60% MoM.

Book a demo to see all signals

For institutional investors. Book with your work email.

Oncovita Filings

Explore SEC and related filing metadata, where available.

Oncovita filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Oncovita's valuation, stock price, and market status.

Is Oncovita a public or private company?

Oncovita is a private company.

What is the current stock price of Oncovita?

Oncovita is a private company, so its shares have no public market price. Caplight tracks Oncovita's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Oncovita worth (valuation)?

Valuation information for Oncovita is not publicly available.

Can I buy Oncovita stock?

Oncovita shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Oncovita's last funding round?

Oncovita's most recent funding round was VC Round on June 25, 2026.

Who are the main investors in Oncovita?

Key investors in Oncovita include Bpifrance.

Will Oncovita IPO soon?

No public IPO plans have been announced for Oncovita.

How can I track Oncovita secondary market activity?

Caplight tracks bids, offers, and trades in Oncovita's shares on secondary markets.

Firmographic Details

HeadquartersParis
Employee Range9
Year Founded2015
Last FundingJun 25, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?